The danger is that the very mechanisms that have allowed systems like Australia’s PBS and New Zealand’s Pharmac to deliver affordable access for the government become national liabilities once MFN is imposed by a much larger market. …
MFN is the name but the consequences will be delivered through GLOBE and GUARD
February 10, 2026 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News -
Tiny fragments of RNA, a giant opportunity for autoimmune disease treatment
February 10, 2026 - - Australian Biotech -
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech -
Immutep reaches midpoint in global Phase 3 lung cancer trial
February 10, 2026 - - Australian Biotech -
Molecule2Market appoints inaugural CEO to lead next phase of growth
February 10, 2026 - - Australian Biotech